Chinese Journal of New Drugs - Digital Cluster of Scitech Periodicals

Home>Journals>Chinese Journal of New Drugs

Chinese Journal of New Drugs

CSCD

ISTIC

PKU

ISSN：1003-3734

CN：11-2850/R

Frequency：Semimonthly

Website：http://www.newdrug.cn

Email：bianjibu@newdrug.cn

Postcode：100098

Articles12737

Citations124451

Funded4496

Impact Factor：2.35

Official Website

Articles

2025 No.23

Total 15 articles

Characteristics analysis of phase Ⅱ clinical trials of new Chinese medicine from 2015 to 2024LEI Xiang, ZHAO Chen, DAI Shun, SUN Hao, XU Ya, OU-YANG Hui-tian, GAO Chun-sheng, CHENG Jin-lian

2465-2471

Analysis patent applications in therapeutic anti-tumor antibodiesBI Qing, LI Jie

2472-2480

The first dual endothelin angiotensin receptor antagonist-Filspari(sparsentan)GUAN Li-ye, ZHAO Jian-qun, TIAN Dong-dong, WU Yu-pei, FANG Ling-zhi

2481-2485

Difficulties and countermeasures for the international acceptance of clinical trial data in ChinaSUN Yi-bu, HAO Zi-ruo, CHEN Yu-wen

2486-2489

From FDA Complete Response Letters on the pharmaceutical assessment of chemical drugs:critical deficiencies and review considerationsREN Feng, CHENG Si-qi, JIANG Tao, CHEN Ai-ping, TANG Zhi-quan, ZHANG Jing-chen

2490-2496

A multidisciplinary review of a new drug from the perspective of FDA Complete Response Letters and review reports:a case study of risperidone microspheresCHENG Si-qi, JIANG Tao, CHEN Ai-ping, TANG Zhi-quan, ZHANG Jing-chen, REN Feng

2497-2501

Discussion on clinical pharmacology of novel anti-obesity drugs:glucagon-like peptide-1 receptor agonistsWANG Jing, LI Li, WEI Chun-min

2502-2507

Research and application progress of biomarkers for Alzheimer's diseaseZHANG Shi-ye, QI Mei, GU Zhi-rong, GE Bin

2508-2516

Application of minimal clinically important difference in economic evaluationLI Yan, HU Hong-fei, ZHAO Min, WANG Di, GAO Wei, LI Hong-chao

2517-2525

Construction of breaking the blind risk assessment content for investigator test site in double-blind clinical trials of traditional Chinese medicine and suggestions for maintenance of blinding in clinical trialsYANG Fang-fang, PAN Ding-ju

2526-2530